

WEEKLY PRODUCT FEATURE

BioDoph-7 Plus®



Biotics Research Corporation • 6801 Biotics Research Drive • Rosenberg TX 77471
(800) 231 - 5777 • www.bioticsresearch.com • biotics@bioticsresearch.com

WPB 13/44

The modern dilemma is that allergies and chronic health conditions are on the rise. Antibacterial soaps, washes, and wipes, chronic dehydration, mercury amalgams, total toxin load, the use of certain pharmaceuticals, and nutrient deficient diets have become a scourge on friendly bacteria. Documented research has indicated important benefits associated with the use of probiotic bacteria, including improved digestion, enzymatic activity, and overall modulating effects on the immune system. Formulated in collaboration with Dr. Gary Lasneski, **BioDoph-7 Plus®** contains a specific blend of 3 prebiotics and 7 probiotics to ensure optimal colonization with bacterial strains recognized for their bioactivity. Each capsule contains 20 billion viable organisms at the time of manufacture and consists of a proprietary blend of Inulin (from Chicory root), Arabinogalactans (from Larch), Marshmallow Root (extract), Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium breve, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, and Streptococcus thermophilus. The sad fact is that far too many people suffer from bowel dysbiosis, manifested as allergies, dermal irritation, fatigue, mood alterations, headaches, leaky gut, diarrhea, constipation, etc. Now further evidence suggests that obesity, diabetes and autoimmune conditions may be linked with altered gut microflora. Given the prevalence of patients that present with any one or more of these symptoms, probiotics have the potential to be the unsung hero of your office. Virtually all patients that present with chronic health challenges should be evaluated for probiotic need.



Research Pertaining to Other Topics of Interest

N-acetylcysteine (NAC) for COPD – The one year HIACE study investigated high dose NAC on stable Chinese COPD patients. In this randomized, double-blind trial of stable COPD patients (ages 50-80 yrs), patients were given either 600 mg of NAC twice daily or placebo. Lung function parameters were measured at baseline and every 16 weeks thereafter for one year. After one year, researchers concluded that the treatment with NAC resulted in significantly improved small airway function and decreased exacerbation frequency in patients with stable COPD.

Tse HN, et al. Chest. 2013 Jul;144(1):106-18. doi: 10.1378chest.12-2357

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.